Phase Ib / II trial evaluating the combination of TG4001 and avelumab in patients with HPV-16 positive recurrent or metastatic malignancies and head and neck squamous cell carcinoma expansion cohort (CCECC)
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: TRANSGENE SA
- Phase: II
- Execution start: 24/05/2019
- End of execution: 30/12/2020
- PI: JOAQUINA MARTINEZ GALAN